Systematic review with meta-analysis: mycophenolate mofetil as a second-line therapy for autoimmune hepatitis.

The overall efficacy of MMF as second-line therapy in AIH was high. Response rate was greater in patients who started the medication due to intolerance to standard therapy as opposed to nonresponse. Overall, MMF was well tolerated, with a low discontinuation rate due to side effects.